Some of the names on the move ahead of the open.» Read More
ACC, ADA, AHA, ASCO, ICAD, TCT. That's just a handful of the acronyms and abbreviations for scientific and medical conferences that I've attended over the years. But this year I might be able to add RITA to my dance card. I'd never heard of her (it) before this morning when I got this press release from Crucell, which owns technology for faster, better, cheaper vaccine manufacturing.
Following are the day’s biggest winners and losers. Find out why shares of Alcoa and Evergreen Solar popped while Apple and Morgan Stanley dropped.
I've got new competition. Sort of. GlaxoSmithKline sent me an email this morning calling my attention to its new external blog, "American Health: More Than Medicine." A pretty long name for a blog, one that screams that it went through the corporate approval wringer, but at least GSK is putting itself out there.
The World Health Organisation warned on Friday against a false sense of security from waning and apparently mild outbreaks of H1N1 flu, saying the worst may not be over.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Cramer makes the call on viewers' favorite stocks.
Stocks turned lower on Thursday as bank stocks backed off their early rally. Fed Reserve Chairman Bernanke said increasing the effectiveness of bank supervision is a "top priority" for the Fed. Treasury Secretary Tim Geithner sought to ease fears about the results by saying that none of the banks being tested face the risk of insolvency. (UPDATED: Stress test results released.)
Out of nowhere late yesterday the FDA approved VNDA's schizophrenia drug with the funky name Fanapt.
Stocks turned lower on Thursday as bank stocks backed off their early rally. Fed Reserve Chairman Bernanke said increasing the effectiveness of bank supervision is a "top priority" for the Fed. Treasury Secretary Tim Geithner sought to ease fears about the results by saying that none of the banks being tested face the risk of insolvency.
Investors can benefit from certain health care companies that will be boosted by the stimulus package, said Les Funtleyder, health care strategist of Miller Tabak.
The futures are down again this morning with uncertainty of the impact that the swine flu will ultimately have. So far, nearly 150 people have died in Mexico from the disease as it continues to spread around the world. Here are some of the stocks that moved most as the story has developed.
Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.
Cubist Pharmaceuticals is up more than 12 percent today with heavy options activity amid rumors that the company will be bought by Swiss drug giant Novartis.
A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.
Even when picking stocks, cash is king, according to Wouter Weijand from Fortis Investments, who likes US funeral service company Hillenbrand, Swiss healthcare manufacturer Novartis, and Australia’s ANZ Bank.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
New Jersey, where I live and work, is known as "The World's Medicine Chest" or "The Silicon Valley of Pharma."
Futures are modestly higher today after yesterday's rally, there are some big Treasury refundings coming, on top of some very large corporate bond issuances coming from the likes of Procter & Gamble, Novartis, and Altria.
Swiss drug maker Roche sees growth slowing this year after its 2008 profit fell 5 percent and missed expectations, hurt by a loss of pandemic Tamiflu sales and the strong Swiss franc.
Following are the day's biggest winners and losers. Find out why shares of Home Depot and Wellpoint popped while Legg Mason and Novartis dropped.